President and CEO
Millennium Pharmaceuticals, Inc. – The Takeda Oncology Company

Dr. Dunsire joined Millennium in July, 2005 with nearly 20 years of experience in commercial, operational, clinical and scientific aspects of a world-leading pharmaceutical business. Her vision for Millennium was to establish a vibrant, growing biotechnology company, which discovers and develops new medicines that change standards of care in cancer and inflammation.

In April of 2008, Millennium was acquired by Takeda Pharmaceuticals of Japan to become the centerpiece for achieving their global vision of Oncology Leadership by 2020. Dr Dunsire remains as President and CEO of Millennium, the Takeda Oncology Company. The current late stage immunology compounds will continue to be developed at Millennium but commercialized through Takeda.

Previously, Dr. Dunsire led the Novartis U.S. Oncology business and played a critical role in the broad development and launch of successful products such as Zometa®, Femara® and Gleevec®. Notably, Dr. Dunsire managed 12 product launches and built the business from approximately $50 million to $2.1 billion in revenues over 10 years.

Earlier in her career, she was a clinical researcher responsible for the implementation of global Phase II and Phase III studies across multiple therapeutic areas, including immunology, endocrinology, neurology, dermatology, oncology and transplantation.

Dr. Dunsire graduated from medical school at the University of Witwatersrand in Johannesburg, South Africa. In 2006, she was also awarded a Doctor of Science, Honoris Causa, from Worcester Polytechnic Institute. Currently, Dr. Dunsire is a board member of Biotechnology Industry Organization (BIO), Allergan, Inc., the Museum of Science (Boston), CancerCare (New York) and Gabrielle's Angel Foundation for Cancer Research. She is also a member of the Massachusetts Women’s forum and the Healthcare Business Women’s Association.

Dr. Dunsire was the 2001 recipient of the American Cancer Society Excalibur award, the 2000 recipient of the Health Care Business Women's Association Rising Star award and also the Creative Spirit award from the Creative Center for Women with Cancer.